Adagio Therapeutics is a clinical-stage biotech developing antibody drugs for infectious diseases, with its lead candidate, adintrevimab, in Phase 3 trials for COVID-19 treatment and prevention.
The company has no approved products and generates minimal revenue (USD 0.05B in 2025), while burning cash with net losses of USD 0.05B in 2025 and USD 0.17B in 2024. Gross margins are high (~93%), but operating margins are deeply negative, indicating no susta
Adagio's potential moat relies on proprietary antibody technology and partnerships with Adimab and Scripps, but it faces intense competition from established players like Pfizer, Moderna, and Regeneron in the COVID-19 space. With no approved product and rapid
Key events, in time order
None yet
None yet
No specific claims about $ADGI were made in the provided posts. The content discusses insider buying in spinoffs and their parents, but does not mention Adagio Therapeutics.
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
